

Prototype test for predicting clinical outcome for melanoma patients

August 15 2008

Investigators from the Melbourne Center of the international Ludwig Institute for Cancer Research (LICR) and Pacific Edge Biotchnology Ltd today reported that they have developed a test to predict whether a patient will progress rapidly from Stage III melanoma to metastatic Stage IV cancer and death.

More than 70% of patients with Stage III melanoma — melanoma that has spread to the lymph nodes — will typically have a rapid time to progression (TTP) to Stage IV melanoma, and pass away within five years of their diagnosis. However, the remaining

Citation: Prototype test for predicting clinical outcome for melanoma patients (2008, August 15) retrieved 12 May 2024 from <https://medicalxpress.com/news/2008-08-prototype-clinical-outcome-melanoma-patients.html>

<p>This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.</p>
--